Suppr超能文献

多发性硬化症的发病机制与治疗策略的再探讨。

Pathogenesis and management of multiple sclerosis revisited.

机构信息

Smt NHL MMC, Ahmedabad, Gujarat, 380006, India; PearResearch, India.

Baroda Medical College, Vadodara, India; PearResearch, India.

出版信息

Dis Mon. 2023 Sep;69(9):101497. doi: 10.1016/j.disamonth.2022.101497. Epub 2022 Oct 22.

Abstract

BACKGROUND

Multiple sclerosis is an autoimmune chronic inflammatory disease characterized by selective destruction of myelin in the CNS neurons (including optic nerve). It was first described in the 19 century and remained elusive owing to the disease's unique relapsing and remitting course. The widespread and debilitating prevalence of multiple sclerosis (MS) has prompted the development of various treatment modalities for its effective management.

METHODS AND OBJECTIVES

A literature review was conducted using the electronic databases PubMed and Google Scholar. The main objective of the review was to compile the advances in pathogenesis, classifications, and evolving treatment modalities for MS.

RESULTS

The understanding of the pathogenesis of MS and the potential drug targets for its precise treatment has evolved significantly over the past decade. The experimental developments are also motivating and present a big change coming up in the next 5 years. Numerous disease-modifying therapies (DMTs) have revolutionized the management of MS: interferon (IFN) preparations, monoclonal antibodies-natalizumab and ocrelizumab, immunomodulatory agents-glatiramer acetate, sphingosine 1-phosphate receptor 1 (S1PR1) modulators (Siponimod) and teriflunomide. The traditional parenteral drugs are now available as oral formulations improving patient acceptability. Repurposing various agents used for related diseases may reinforce the drug reserve to manage MS and are under trials. Although at a nascent phase, strategies to enhance re-myelination by stimulating oligodendrocytes are fascinating and hold promise for better outcomes in patients with MS.

CONCLUSIONS

The recent past has seen staggering inclusions to the management of multiple sclerosis catalyzing a significant turnabout in our approach to diagnosis, treatment, and prognosis. Since the advent of DMTs various other oral and injectable agents have been approved. The advances in MS therapeutics and diagnostics have laid the ground for further research and development to enhance the quality of life of afflicted patients.

摘要

背景

多发性硬化症是一种自身免疫性慢性炎症性疾病,其特征是中枢神经系统神经元(包括视神经)的髓鞘选择性破坏。它于 19 世纪首次被描述,由于疾病独特的复发和缓解过程,一直难以捉摸。多发性硬化症(MS)的广泛和使人衰弱的流行促使人们开发了各种治疗方法来有效管理这种疾病。

方法和目的

使用电子数据库 PubMed 和 Google Scholar 进行了文献回顾。审查的主要目的是汇编多发性硬化症的发病机制、分类和不断发展的治疗方法方面的进展。

结果

在过去的十年中,对多发性硬化症发病机制的理解以及针对其精确治疗的潜在药物靶点发生了重大变化。实验的发展也令人振奋,并为未来 5 年带来了重大变化。许多疾病修正疗法(DMT)彻底改变了多发性硬化症的治疗:干扰素(IFN)制剂、单克隆抗体-那他珠单抗和奥瑞珠单抗、免疫调节剂-醋酸格拉替雷、鞘氨醇 1-磷酸受体 1(S1PR1)调节剂(西尼莫德)和特立氟胺。传统的注射药物现在已作为口服制剂提供,提高了患者的接受度。重新利用用于相关疾病的各种药物可能会增强用于治疗多发性硬化症的药物储备,并正在进行试验。虽然处于萌芽阶段,但通过刺激少突胶质细胞增强髓鞘再生的策略令人着迷,并为多发性硬化症患者带来更好的结果带来了希望。

结论

最近的进展见证了多发性硬化症管理的惊人纳入,这极大地改变了我们对诊断、治疗和预后的方法。自从 DMT 问世以来,已经批准了各种其他口服和注射药物。多发性硬化症治疗和诊断方面的进步为进一步的研究和开发奠定了基础,以提高受影响患者的生活质量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验